LIST OF TABLES
UU
TABLE 1 MERCK KGAA, R&D ACTIVITIES
TABLE 2 LONZA, R&D ACTIVITIES
TABLE 3 THERMO FISHER SCIENTIFIC INC, R&D ACTIVITIES
TABLE 4 F. HOFFMANN-LA ROCHE LTD, R&D ACTIVITIES
TABLE 5 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 6 EUROPE KITS & REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 7 EUROPE KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 8 EUROPE INSTRUMENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 9 EUROPE SERVICES IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 10 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES, 2017-2026 (USD MILLION)
TABLE 11 EUROPE MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 12 EUROPE POLYMERASE CHAIN REACTION IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 13 EUROPE ELISA IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 14 EUROPE DNA STAINING/INDIRECT ASSAY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 15 EUROPE ENZYMATIC METHODS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 16 EUROPE OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 17 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 18 EUROPE RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 19 EUROPE RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 20 EUROPE RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 21 EUROPE UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 22 EUROPE UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 23 EUROPE UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 24 EUROPE GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 25 EUROPE GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 26 EUROPE GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 27 EUROPE CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 28 EUROPE CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 29 EUROPE CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 30 EUROPE MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 31 EUROPE MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 32 EUROPE MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 33 EUROPE OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 34 EUROPE OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 35 EUROPE OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 36 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 37 EUROPE HOSPITALS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 38 EUROPE DIAGNOSTIC LABORATORIES IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 39 EUROPE KITS & REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 40 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
TABLE 41 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 42 EUROPE KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 43 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 44 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 45 EUROPE UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 46 EUROPE UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 47 EUROPE RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 48 EUROPE RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 49 EUROPE CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 50 EUROPE CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 51 EUROPE MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 52 EUROPE MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 53 EUROPE GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 54 EUROPE GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 55 EUROPE OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 56 EUROPE OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 57 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 58 GERMANY MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 59 GERMANY KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 60 GERMANY MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 61 GERMANY MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 62 GERMANY UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 63 GERMANY UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 64 GERMANY RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 65 GERMANY RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 66 GERMANY CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 67 GERMANY CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 68 GERMANY MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 69 GERMANY MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 70 GERMANY GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 71 GERMANY GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 72 GERMANY OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 73 GERMANY OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 74 GERMANY MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 75 U.K. MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 76 U.K. KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 77 U.K. MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 78 U.K. MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 79 U.K. UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 80 U.K. UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 81 U.K. RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 82 U.K. RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 83 U.K. CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 84 U.K. CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 85 U.K. MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 86 U.K. MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 87 U.K. GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 88 U.K. GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 89 U.K. OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 90 U.K. OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 91 U.K. MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 92 FRANCE MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 93 FRANCE KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 94 FRANCE MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 95 FRANCE MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 96 FRANCE UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 97 FRANCE UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 98 FRANCE RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 99 FRANCE RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 100 FRANCE CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 101 FRANCE CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 102 FRANCE MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 103 FRANCE MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 104 FRANCE GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 105 FRANCE GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 106 FRANCE OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 107 FRANCE OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 108 FRANCE MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 109 ITALY MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 110 ITALY KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 111 ITALY MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 112 ITALY MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 113 ITALY UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 114 ITALY UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 115 ITALY RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 116 ITALY RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 117 ITALY CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 118 ITALY CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 119 ITALY MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 120 ITALY MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 121 ITALY GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 122 ITALY GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 123 ITALY OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 124 ITALY OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 125 ITALY MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 126 SPAIN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 127 SPAIN KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 128 SPAIN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 129 SPAIN MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 130 SPAIN UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 131 SPAIN UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 132 SPAIN RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 133 SPAIN RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 134 SPAIN CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 135 SPAIN CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 136 SPAIN MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 137 SPAIN MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 138 SPAIN GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 139 SPAIN GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 140 SPAIN OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 141 SPAIN OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 142 SPAIN MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 143 NETHERLANDS MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 144 NETHERLANDS KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 145 NETHERLANDS MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 146 NETHERLANDS MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 147 NETHERLANDS UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 148 NETHERLANDS UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 149 NETHERLANDS RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 150 NETHERLANDS RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 151 NETHERLANDS CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 152 NETHERLANDS CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 153 NETHERLANDS MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 154 NETHERLANDS MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 155 NETHERLANDS GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 156 NETHERLANDS GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 157 NETHERLANDS OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 158 NETHERLANDS OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 159 NETHERLANDS MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 160 SWITZERLAND MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 161 SWITZERLAND KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 162 SWITZERLAND MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 163 SWITZERLAND MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 164 SWITZERLAND UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 165 SWITZERLAND UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 166 SWITZERLAND RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 167 SWITZERLAND RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 168 SWITZERLAND CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 169 SWITZERLAND CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 170 SWITZERLAND MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 171 SWITZERLAND MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 172 SWITZERLAND GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 173 SWITZERLAND GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 174 SWITZERLAND OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 175 SWITZERLAND OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 176 SWITZERLAND MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 177 RUSSIA MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 178 RUSSIA KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 179 RUSSIA MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 180 RUSSIA MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 181 RUSSIA UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 182 RUSSIA UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 183 RUSSIA RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 184 RUSSIA RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 185 RUSSIA CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 186 RUSSIA CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 187 RUSSIA MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 188 RUSSIA MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 189 RUSSIA GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 190 RUSSIA GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 191 RUSSIA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 192 RUSSIA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 193 RUSSIA MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 194 BELGIUM MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 195 BELGIUM KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 196 BELGIUM MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 197 BELGIUM MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 198 BELGIUM UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 199 BELGIUM UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 200 BELGIUM RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 201 BELGIUM RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 202 BELGIUM CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 203 BELGIUM CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 204 BELGIUM MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 205 BELGIUM MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 206 BELGIUM GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 207 BELGIUM GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 208 BELGIUM OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 209 BELGIUM OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 210 BELGIUM MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 211 TURKEY MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 212 TURKEY KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 213 TURKEY MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 214 TURKEY MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 215 TURKEY UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 216 TURKEY UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 217 TURKEY RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 218 TURKEY RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 219 TURKEY CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 220 TURKEY CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 221 TURKEY MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 222 TURKEY MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 223 TURKEY GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 224 TURKEY GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 225 TURKEY OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 226 TURKEY OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 227 TURKEY MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 228 REST OF EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)

LIST OF FIGURE

LIST OF FIGURES

FIGURE 1 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: SEGMENTATION
FIGURE 2 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: DATA VALIDATION MODEL
FIGURE 3 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: DROC ANALYSIS
FIGURE 4 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: EUROPE VS REGIONAL
FIGURE 5 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET
FIGURE 10 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: SEGMENTATION
FIGURE 11 INCREASING CASES OF MYCOPLASMA INFECTIONS AND TECHNOLOGIAL ADVANCEMENTS IN THE IDENTIFICATION TECHNIQUES ARE EXPECTED TO DRIVE THE EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
FIGURE 12 KITS & REAGENTS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET IN THE FORECAST PERIOD OF 2019 & 2026
FIGURE 13 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY TYPE, 2018
FIGURE 14 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY TECHNIQUES, 2018
FIGURE 15 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY DISEASE AREA, 2018
FIGURE 16 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY END USER, 2018
FIGURE 17 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: SNAPSHOT (2018)
FIGURE 18 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018)
FIGURE 19 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2019 & 2026)
FIGURE 20 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018 & 2026)
FIGURE 21 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY PRODUCTS (2019-2026)
FIGURE 22 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: COMPANY SHARE 2018 (%)